Loading
AURELIA showed that adding bevacizumab to single-drug chemotherapy for ovarian cancer that has stopped responding to platinum doubled the time before the cancer grew again, from 3.4 to 6.7 months, and more than doubled the response rate, though it did not clearly lengthen life.
AURELIA was an open-label phase 3 trial in 361 women with platinum-resistant ovarian cancer randomised to the investigator's choice of weekly paclitaxel, pegylated liposomal doxorubicin or topotecan, alone or with bevacizumab. The primary endpoint was progression-free survival.
Median progression-free survival was 6.7 months with bevacizumab against 3.4 months with chemotherapy alone (hazard ratio 0.48), the response rate 27.3 against 11.8 percent and median overall survival 16.6 against 13.3 months (hazard ratio 0.85, not significant). Hypertension and proteinuria were more common with bevacizumab and gastrointestinal perforation occurred in 2.2 percent. The trial led to approval of bevacizumab with chemotherapy for platinum-resistant disease in the United States in November 2014, which is how the corpus's platinum-resistant ovarian cancer page cites it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
361 enrolled.
95% CI 5.62 to 7.79 · 95% CI 2.10 to 3.75
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Bevacizumab + single-agent chemotherapy | - | 6.7 months | 0.48 (0.38 to 0.6) | <0.001 | link |
| Single-agent chemotherapy | - | 3.4 months | ||||
| Progression-free survival (registry results, November 2011 cut-off) | Bevacizumab + single-agent chemotherapy | - | 6.8 months | 0.46 (0.366 to 0.577) | <0.0001 | link |
| Single-agent chemotherapy | - | 3.4 months | ||||
| Objective response rate (RECIST) | Bevacizumab + single-agent chemotherapy | - | 27.3% | - | 0.001 | link |
| Single-agent chemotherapy | - | 11.8% | ||||
| Overall survival | Bevacizumab + single-agent chemotherapy | - | 16.6 months | 0.85 (0.66 to 1.08) | 0.174 | link |
| Single-agent chemotherapy | - | 13.3 months | ||||
| Gastrointestinal perforation | Bevacizumab + single-agent chemotherapy | - | 2.2% | - | - | link |
Shares Topotecan, Cytotoxic chemotherapy and the tag soc-trials.
Shares Topotecan, Cytotoxic chemotherapy and the tag soc-trials.
Shares Roche / Genentech, Cytotoxic chemotherapy and the tag soc-trials.
Shares Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy and the tag soc-trials.
Shares Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy and the tag soc-trials.
Shares Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy and the tag soc-trials.
Shares Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy and the tag soc-trials.
Shares Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy and the tag soc-trials.